• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lecanemab in Early Alzheimer's Disease. Reply.

作者信息

van Dyck Christopher H, Sabbagh Marwan, Cohen Sharon

机构信息

Yale School of Medicine, New Haven, CT

Barrow Neurological Institute, Phoenix, AZ.

出版信息

N Engl J Med. 2023 Apr 27;388(17):1631-1632. doi: 10.1056/NEJMc2301380.

DOI:10.1056/NEJMc2301380
PMID:37099355
Abstract
摘要

相似文献

1
Lecanemab in Early Alzheimer's Disease. Reply.用于早期阿尔茨海默病的lecanemab。回复。
N Engl J Med. 2023 Apr 27;388(17):1631-1632. doi: 10.1056/NEJMc2301380.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.CLARITY AD：早期阿尔茨海默病中lecanemab的III期试验亚洲区域分析
J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.
4
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.用lecanemab进行单克隆治疗轻度阿尔茨海默病：一项系统评价和荟萃分析。
Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.
5
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.Lecanemab Clarity AD：早期阿尔茨海默病的一项随机、双盲 3 期临床试验的生活质量结果。
J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123.
6
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.抗淀粉样蛋白β单克隆抗体治疗阿尔茨海默病的疗效和安全性的系统评价。
Expert Opin Biol Ther. 2024 Nov;24(11):1261-1269. doi: 10.1080/14712598.2024.2416947. Epub 2024 Nov 12.
7
The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.与安慰剂相比，每两周一次10mg/kg剂量的lecanemab治疗阿尔茨海默病患者的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Neurol Sci. 2024 Aug;45(8):3583-3597. doi: 10.1007/s10072-024-07477-w. Epub 2024 Apr 3.
8
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.在轻度认知障碍和阿尔茨海默病患者中，比较 donanemab、lecanemab、aducanumab 和锂对认知功能的疗效、耐受性和可接受性：一项系统评价和网络荟萃分析。
Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20.
9
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics.用于早期阿尔茨海默病的莱卡奈单抗：法国记忆诊所联合会的合理使用建议
J Prev Alzheimers Dis. 2025 Apr;12(4):100094. doi: 10.1016/j.tjpad.2025.100094. Epub 2025 Feb 25.
10
Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.新型抗淀粉样蛋白-β（Aβ）单克隆抗体 Lecanemab 治疗阿尔茨海默病的系统评价。
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839.

引用本文的文献

1
The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer's disease.NMDAR/TRPM4死亡复合体是阿尔茨海默病5xFAD小鼠模型中疾病进展的主要促进因素。
Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03143-5.
2
Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer's disease.优化阿尔茨海默病血浆生物标志物的检测时机及成本效益应用。
Alzheimers Res Ther. 2025 Aug 20;17(1):194. doi: 10.1186/s13195-025-01851-2.
3
CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients.
几丁质酶1（CHIT1）和二甲基精氨酸二甲胺水解酶1（DDAH1）水平与阿尔茨海默病患者淀粉样蛋白相关成像异常风险概况相关。
Alzheimers Res Ther. 2025 Jul 22;17(1):169. doi: 10.1186/s13195-025-01799-3.
4
Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain.开发用于中和脑中蜱传脑炎病毒的血脑屏障穿透抗体。
mSphere. 2025 Jul 29;10(7):e0018425. doi: 10.1128/msphere.00184-25. Epub 2025 Jul 7.
5
Therapeutic effects of miR-937-3p by targeting NTN1 expression and regulating apoptosis in an Aβ-induced neuronal cell death.通过靶向NTN1表达并调节细胞凋亡，miR-937-3p在Aβ诱导的神经元细胞死亡中的治疗作用。
Sci Rep. 2025 Jul 2;15(1):23611. doi: 10.1038/s41598-025-08015-0.
6
Variable and interactive effects of Sex, APOE ε4 and TREM2 on the deposition of tau in entorhinal and neocortical regions.性别、载脂蛋白Eε4（APOE ε4）和触发受体表达于髓样细胞2（TREM2）对内嗅皮质和新皮质区域tau蛋白沉积的可变及交互作用。
Nat Commun. 2025 Jul 1;16(1):5812. doi: 10.1038/s41467-025-60370-8.
7
Therapeutic time window of disease-modifying therapy for early Alzheimer's disease.早期阿尔茨海默病改善病情治疗的治疗时间窗
Alzheimers Dement (N Y). 2025 May 29;11(2):e70102. doi: 10.1002/trc2.70102. eCollection 2025 Apr-Jun.
8
An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.一项关于贝齐司替林治疗与轻度至中度可能的阿尔茨海默病患者生物年龄加速降低、临床指标改善及生物标志物变化相关的探索性分析。
Front Neurosci. 2025 May 2;19:1516746. doi: 10.3389/fnins.2025.1516746. eCollection 2025.
9
Alzheimer's disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids for disease modeling and drug discovery.阿尔茨海默病患者脑提取物在新型血管化神经免疫类器官中诱发多种病理变化，用于疾病建模和药物发现。
Mol Psychiatry. 2025 May 2. doi: 10.1038/s41380-025-03041-w.
10
Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathology.用于评估脑淀粉样病变的基于血液的多生物标志物模型的开发与临床验证
medRxiv. 2025 Apr 24:2025.02.27.25322892. doi: 10.1101/2025.02.27.25322892.